Work Package 6 – Industrial developments


According to the specific activity of each industrial partner, raw biomass, extracts, pure compounds, enzymes, and biotechnological equipment will be evaluated for potential industrial developments.


Main activities

A set of different technologies will be applied in order to proceed promising hit compounds into pharmaceutical evaluation, including x-ray-crystallography, in silico homology searches for identification of potential disease targets and setting–up selectivity panels for evaluating potential side effects. The results of these will then be used to come up with educated suggestions how an identified hit compound can be improved. Cosmeceutical ingredients and fine products will be developed subject to safety and efficacy assessments and the production of selected formulations will be scaled up. Organisms and/or extracts showing potential use as nutraceuticals from the biological screenings in WP4 will be evaluated on a commercial and regulatory basis. In addition to these applications, bioconversions catalyzed by whole cells, their crude extracts or pure recombinant enzymes of interest from screening in WP3 will be evaluated.



Work package leader : APIVITA
Partners involved : CRELUX, BICT, PGT, ASTAREAL

eu-flagTASCMAR is a collaborative European research project funded by the European Union’s Horizon 2020 research and innovation programme, under grant agreement N° 634674.